RxDoctor Payments Data

David Schwimmer, MD

Gastroenterology · Palm Beach Gardens, FLNPI 1245641380

Payments from drug & device makers

$24,282in general payments, 2019–2025

Across 421 payments — averaging $57.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$834
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$624
  • Bristol Myers Squibb$417
  • QOL Medical, LLC$407
  • plus $3K from 29 others

What the payments were for

  • Speaking & faculty fees$13,77557%
  • Travel & lodging$4332%
  • Food & beverage$9,60340%
  • Education$3892%
  • Gifts$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,282 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$148,890
Medicare patients
437
Services billed
2,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$349,315
Humira(Cf) PenAdalimumab26$231,636
CreonLipase/Protease/Amylase12$33,010
MounjaroTirzepatide15$16,019
ClenpiqSod Picosulf/Mag Ox/Citric Ac40$6,841
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C45$6,514
Pantoprazole Sodium229$4,265
CholestyramineCholestyramine (With Sugar)26$1,339
Colestipol Hcl25$1,125
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates12$758
Ondansetron OdtOndansetron12$178
Omeprazole29$146
Rabeprazole Sodium12$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,562$349,31513 claims
AbbVieCreon$17,793$33,01012 claims
Lilly USA, LLCMounjaro$60$16,01915 claims
Ferring Pharmaceuticals Inc.Clenpiq$18$6,84140 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$624$6,51445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →